These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 9816334

  • 1. Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors?
    Gerl A, Lamerz R, Clemm C, Mann K, Hartenstein R, Wilmanns W.
    Clin Cancer Res; 1996 Sep; 2(9):1565-70. PubMed ID: 9816334
    [Abstract] [Full Text] [Related]

  • 2. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors.
    Toner GC, Geller NL, Tan C, Nisselbaum J, Bosl GJ.
    Cancer Res; 1990 Sep 15; 50(18):5904-10. PubMed ID: 1697503
    [Abstract] [Full Text] [Related]

  • 3. Is serum tumor marker half-life a guide to prognosis in metastatic nonseminomatous germ cell tumors?
    Gerl A, Lamerz R, Mann K, Clemm C, Wilmanns W.
    Anticancer Res; 1997 Sep 15; 17(4B):3047-9. PubMed ID: 9329598
    [Abstract] [Full Text] [Related]

  • 4. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma.
    Stevens MJ, Norman AR, Dearnaley DP, Horwich A.
    J Clin Oncol; 1995 Jan 15; 13(1):87-92. PubMed ID: 7528272
    [Abstract] [Full Text] [Related]

  • 5. Predictive value of marker half-life in relapsed and nonrelapsed nonseminomatous germ cell testicular tumor patients undergoing chemotherapy.
    Keskin S, Ekenel M, Başaran M, Bavbek S.
    Am J Clin Oncol; 2012 Aug 15; 35(4):369-72. PubMed ID: 22814307
    [Abstract] [Full Text] [Related]

  • 6. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
    You B, Fronton L, Boyle H, Droz JP, Girard P, Tranchand B, Ribba B, Tod M, Chabaud S, Coquelin H, Fléchon A.
    Urology; 2010 Aug 15; 76(2):423-9.e2. PubMed ID: 20472276
    [Abstract] [Full Text] [Related]

  • 7. Prognostic factors in metastatic nonseminomatous germ cell tumours.
    Hanson PR, Belitsky P, Millard OH, Lannon SG.
    Can J Surg; 1993 Dec 15; 36(6):537-40. PubMed ID: 7504978
    [Abstract] [Full Text] [Related]

  • 8. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers.
    Habuchi T, Kamoto T, Hara I, Kawai K, Nakao M, Nonomura N, Kobayashi T, Ogawa O, Kamidono S, Akaza H, Okuyama A, Kato T, Miki T.
    Cancer; 2003 Oct 15; 98(8):1635-42. PubMed ID: 14534879
    [Abstract] [Full Text] [Related]

  • 9. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors.
    Fizazi K, Culine S, Kramar A, Amato RJ, Bouzy J, Chen I, Droz JP, Logothetis CJ.
    J Clin Oncol; 2004 Oct 01; 22(19):3868-76. PubMed ID: 15302906
    [Abstract] [Full Text] [Related]

  • 10. Significance of elevated preoperative alpha-fetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumors.
    Kobayashi T, Kawakita M, Terachi T, Habuchi T, Ogawa O, Kamoto T.
    J Surg Oncol; 2006 Dec 01; 94(7):619-23. PubMed ID: 17111392
    [Abstract] [Full Text] [Related]

  • 11. The value of AFP and HCG half lives in predicting the efficacy of combination chemotherapy in patients with non-seminomatous germ cell tumors of the testis.
    Willemse PH, Sleijfer DT, Schraffordt Koops H, De Bruijn HW, Oosterhuis JW, Brouwers TM, Ockhuizen T, Marrink J.
    Oncodev Biol Med; 1981 Dec 01; 2(1-2):129-34. PubMed ID: 6170953
    [Abstract] [Full Text] [Related]

  • 12. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
    Culine S, Kramar A, Théodore C, Geoffrois L, Chevreau C, Biron P, Nguyen BB, Héron JF, Kerbrat P, Caty A, Delva R, Fargeot P, Fizazi K, Bouzy J, Droz JP, Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
    J Clin Oncol; 2008 Jan 20; 26(3):421-7. PubMed ID: 18202419
    [Abstract] [Full Text] [Related]

  • 13. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
    Kumano M, Miyake H, Hara I, Muramaki M, Takenaka A, Fujisawa M.
    Hinyokika Kiyo; 2007 Dec 20; 53(12):851-6. PubMed ID: 18203521
    [Abstract] [Full Text] [Related]

  • 14. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors.
    Beck SD, Foster RS, Bihrle R, Donohue JP.
    Urology; 2007 Mar 20; 69(3):557-9. PubMed ID: 17382165
    [Abstract] [Full Text] [Related]

  • 15. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.
    Mazumdar M, Bajorin DF, Bacik J, Higgins G, Motzer RJ, Bosl GJ.
    J Clin Oncol; 2001 May 01; 19(9):2534-41. PubMed ID: 11331333
    [Abstract] [Full Text] [Related]

  • 16. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.
    Fosså SD, Stenning SP, Gerl A, Horwich A, Clark PI, Wilkinson PM, Jones WG, Williams MV, Oliver RT, Newlands ES, Mead GM, Cullen MH, Kaye SB, Rustin GJ, Cook PA.
    Br J Cancer; 1999 Jul 01; 80(9):1392-9. PubMed ID: 10424741
    [Abstract] [Full Text] [Related]

  • 17. The prognostic value of tumor markers in newly diagnosed patients with primary central nervous system germ cell tumors.
    Kim A, Ji L, Balmaceda C, Diez B, Kellie SJ, Dunkel IJ, Gardner SL, Sposto R, Finlay JL.
    Pediatr Blood Cancer; 2008 Dec 01; 51(6):768-73. PubMed ID: 18802946
    [Abstract] [Full Text] [Related]

  • 18. Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors.
    Vogelzang NJ, Lange PH, Goldman A, Vessela RH, Fraley EE, Kennedy BJ.
    Cancer Res; 1982 Nov 01; 42(11):4855-61. PubMed ID: 6181870
    [Abstract] [Full Text] [Related]

  • 19. Use of human chorionic gonadotropin and alpha-fetoprotein radioimmunoassays: specificity and apparent half-life determination after delivery and in patients with germ cell tumors.
    Mann K, Lamerz R, Hellmann T, Kümper HJ, Staehler G, Karl HJ.
    Oncodev Biol Med; 1980 Nov 01; 1(4-5):301-12. PubMed ID: 6169065
    [Abstract] [Full Text] [Related]

  • 20. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection.
    Beck SD, Foster RS, Bihrle R, Einhorn LH, Donohue JP.
    J Clin Oncol; 2005 Sep 01; 23(25):6149-56. PubMed ID: 16135481
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.